Stockreport

AVEO Oncology to Present Final Overall Survival Analysis from the Phase 3 TIVO-3 Trial of Tivozanib in Renal Cell Carcinoma at the ASCO 2020 Virtual Scientific Program

AVEO Pharmaceuticals, Inc.  (AVEO) 
Last aveo pharmaceuticals, inc. earnings: 3/16 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: investor.aveooncology.com
PDF CAMBRIDGE, Mass.--(BUSINESS WIRE)--AVEO Oncology (NASDAQ: AVEO) today announced that the final overall survival analysis from its pivotal Phase 3 TIVO-3 trial compar [Read more]